Study, year | Study design | Type of HF | Inclusion Criteria | Exclusion Criteria | Study comparison | Type of statins | Primary endpoints | Follow-up |
---|---|---|---|---|---|---|---|---|
Horwich et al. 2004 | Prospective cohort | HFrEF | HF patients | EF > 40% Baseline incomplete data | Statins: Control | Not specified | All-cause mortality; mortality mortality | 12 mo |
Sola et al. 2005 | Prospective cohort | HFrEF | HF patients EF ≤35% NYHA II-III | Prescribed statins > 1 year; intolerance to statins | Statins: Control | Atorvastatin Fluvastatin Pitavastatin Simvastatin | All-cause mortality; Hospitalization | 24 5 mo |
Fukuta et al. 2005 | Prospective cohort | HFpEF | HF patients | EF < 50% Significant valvular disease; prosthetic valve | Statins: Control | Atorvastatin Simvastatin Pravastatin Fluvastatin | All-cause mortality; Hospitalizations | 21 ± 12 mo |
Hong et al. 2005 | Prospective cohort | HFrEF | HF patients < 40% | HF patients with EF > 40% | Statins: Control | Simvastatin | 12 mo | |
Go et al. 2006 | Prospective cohort | HFrEF | HF patients | Statins: Control | Not specified | All-cause mortality; Hospitalizations | 28 mo | |
Kjekshus et al. 2007 CORONA | RCTs | HFrEF | HF patients, EF < 40%, NYHA II-IV | previous statin- induced myopathy or hypersensitivity decompensated HF | Statins: Control | Rosuvastatin | CV death Non-fatal MI Stroke | 38.2 mo |
Huan et al. 2007 | Prospective cohort | HFrEF | HF patients with LVSD | HF patients with LVDD | Statins: Control | Not specified | All-cause mortality; | 36 mo |
Coleman et al. 2008 | Prospective cohort | HFrEF | HF patients EF < 40%,und--ergoing ICD | Statins: Control | Not specified | All-cause Mortality VT/VF incidence | 31 mo | |
Roik et al. 2008 | Prospective cohort | HFpEF | HF patients with preserved EF | LVEF ≤45%, ACS cardiogenic shock severe AS, etc. | Statins: Control | Simvastatin Atorvastatin | All-cause mortality; Hospitalization | 12 mo |
Tevazzi et al. 2008 the GISSI-HF trial | RCTs | HFrEF | HF patients NYHA II-IV | Non-cardiac comorbidity (cancer) | Statins: Control | Rosuvastatin | All-cause mortality; Hospitalization | 3.9 y |
Gomez-Soto et al. 2010 | Prospective cohort | HFpEF | HF patients with preserved EF | HF patients with reduced EF | Statins: Control | Not specified | All-cause mortality; CV mortality Hospitalization | 34.6 mo |
Kaneko et al. 2013 | Prospective cohort | HFpEF | HF patients with EF ≥50% | Valvular heart disease EF < 50% | Statins: Control | Not specified | CV mortality Hospitalization | 3 y |
Yap et al. 2015 | Prospective cohort | HFpEF | HF patients with EF ≥50% | Incomplete follow-up Non-documented EF | Statins: Control | Not specified | All-cause mortality; | 2 y |
Nochioka et al. 2015 | Prospective cohort | HFpEF | HF patients with stages B-D | NR | Statins: Control | Not specified | All-cause mortality; Hospitalization | 3 y |
Alehagen U et al. 2015 | Prospective cohort | HFpEF | HF patients with EF ≥50% | HF patients with EF < 50% | Statins: Control | Not specified | All-cause mortality; | 12 mo |
Alehagen et al. 2015 | Prospective cohort | HFrEF | HF patients | HF patients with EF ≥50% | Statins: Control | Not specified | All-cause mortality; | 24 mo |
Tsujimoto et al. 2018 | Prospective cohort | HFpEF | HF patients with preserved EF | HOCMP systemic illness with l Life expectancy < 3 y; | All-cause mortality; CV and Non-CV mortality; | 3.3 y |